-
Xeltis AG Enrolls First Patient in US Pivotal Trial for aXess with FDA BTD Status
•
Holland-based Xeltis AG has announced the enrollment of the first patient in a US-staged pivotal trial for its flagship product, aXess, which has been granted Breakthrough Device Designation (BTD) status by the US FDA. This marks a significant milestone in the development and potential approval of aXess, a novel medical…
-
Grand Pharma Acquires Stake in Xeltis and Licenses aXess for Hemodialysis in Greater China
•
China-based Grand Pharmaceutical Group Limited (HKG: 0512) announced the acquisition of an 11% stake in Holland-based Xeltis AG, along with an exclusive license for the development, manufacturing, and commercialization of Xeltis’s endogenous tissue repair product aXess in Greater China. The deal, valued at €15 million ($15.2 million), grants Grand Pharma…
